Orexo says its first preclinical in vivo study of an oral semaglutide built on AmorphOX showed promising bioavailability. Animal data only so far.
Recap by typeshit. Full story at TipRanks.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
28:35
An animated look at how many people are taking retatrutide before any approval, and what that means for the gray market.
Edinburgh researchers say no more than half the drop in heart disease traced back to known risk factors, and suggest treating semaglutide as a heart drug too.
Loading…